{
    "nct_id": "NCT05653349",
    "official_title": "A Phase III, Randomized, Double-blind Study of Ianalumab (VAY736) Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (VAYHIT1)",
    "inclusion_criteria": "* Signed informed consent prior to participation in the study.\n* Male or female participants aged 18 years and older on the day of signing informed consent\n* Primary ITP diagnosed within 3 months before initiating first-line ITP therapy (corticosteroids, IVIG)\n* Platelet count below 30 G/L before starting any first-line ITP therapy (corticosteroids, IVIG)\n* Response (platelet count >=50 G/L) to corticosteroids (+/- IVIG) at any time prior to randomization. Note: Platelet count measured within 7 days of platelet transfusion will not be considered as response.\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 100 Years",
    "exclusion_criteria": "* Evans syndrome or any other cytopenia (patients with low grade anemia related to bleeding or iron deficiency are eligible)\n* Current life-threatening bleeding\n* Previous ITP treatment, including splenectomy, except for corticosteroids and/or IVIG initiated as first-line therapy for up to 28 days before randomization and rescue corticosteroids and/or IVIG given prior to confirmed diagnosis of primary ITP .\n* Prior use of B-cell depleting therapy (e.g., rituximab).\n* Absolute neutrophil count below 1.0 G/L at randomization\n* Participants with concurrent coagulation disorders and/or receiving anti-platelet or anticoagulant medication with an exemption of low dose of acetylsalicylic acid\n\nOther protocol-defined Inclusion/Exclusion may apply.",
    "miscellaneous_criteria": ""
}